Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts
Versant Ventures has once again racked up a record new biotech fund. Fund VI has landed, weighing in at $400 million, well ahead of the initial $350 million goal and Fund V’s $305 million total.
That’s enough cash to back some two dozen upstarts in the biotech world, and you can expect a sizable amount to be directed at the emerging companies being forged in its discovery incubators in Canada and the US: Blueline Bioscience in Toronto, Highline Therapeutics in New York, and Inception Sciences in San Diego, Vancouver and Montreal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
